A molecular model of the F12 biotherapy shows the fold of its polypeptide backbone. Residual T-cell epitopes are mapped onto the structure and colored from white (no epitopes) to dark red (dense overlapping epitopes). The muted red coloring indicates that T-cell epitopes have been broadly silenced in the engineered F12 variant, and this reduced epitope content underlies the molecule’s improved safety and efficacy profile.
The Centers for Disease Control and Prevention (CDC) has prioritized finding effective treatment of methicillin-resistant Staphylococcus aureus (MRSA), one of the most common bacterial pathogens and the single most deadly drug-resistant bacteria in the United States. Now, a new study led by Dartmouth engineering researchers shows promise for an engineered lysin-based antibacterial agent that may enable safe, repeated dosing to treat life-threatening infections by MRSA and other types of S. aureus.
In recent years, lysins—enzymes naturally produced by microbes and associated viruses—have shown potential to treat S. aureus, which can rapidly acquire resistance to other types of antibiotic drugs.
“Lysins are one of the most promising next-generation antibiotics. They kill drug-sensitive and drug-resistant bacteria with equal efficacy, they can potentially suppress new resistance phenotypes, and they also have this laser-like precision,” said Dartmouth engineering professor and corresponding author Karl Griswold.
While there is promise in lysins, development has been slowed due to concerns that they prompt humans’ immune systems to develop antidrug antibodies, which can have negative side effects including life-threatening hypersensitivity reactions.
That’s why the Dartmouth engineering team—which also included researchers in Dartmouth’s computer science department, The Lundquist Institute at Harbor-UCLA Medical Center, Lyticon, and Stealth Biologics—engineered and patented F12, a new lysin-based antibacterial agent. F12 is essentially able to hide from the human immune system (due to T cell epitope deletion), and therefore does not cause the same negative side effects as unmodified, natural lysins.
F12 is the first lysin-based treatment with the potential to be used multiple times on a single patient, making it ideal to treat particularly persistent drug-resistant and drug-sensitive infections. Preclinical studies showed the efficacy of F12 does not diminish with repeated doses, while two other anti-MRSA lysin treatments currently in clinical trials are only designed to be used a single time.
“We have engineered this super potent, super effective anti-MRSA biotherapeutic, and we’ve done it in a way that renders it compatible with and largely invisible to the human immune system. By making it a safer drug, we’ve enabled the possibility of dosing multiple times in order to treat even the most highly refractory infections,” said Griswold.
The team’s paper, “Globally deimmunized lysostaphin evades human immune surveillance and enables highly efficacious repeat dosing,” was published earlier today by Science Advances. The work was the result of two grants from the National Institutes of Health (NIH) totaling $1.7 million.
The paper details the treatment’s positive results in rabbits, mice with partially-humanized immune systems, and studies with extracted human immune cells. Griswold believes the antibacterial agent could be ready for human clinical trials as soon as 2023.
“This is the first report of a translation-ready deimmunized lysin, and F12 has serious, bonafide clinical potential,” said Griswold.
Further studies of F12 will examine synergy with standard-of-care antibacterial chemotherapies. Preliminary results suggest the combinations are extremely potent and suppress drug-resistance phenotypes.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Drug resistant bacteria
- Opinion: A cornerstone of modern medicine is on the brink of collapse
Without newer, more potent antibiotics, we may soon face a global public health crisis as devastating as COVID-19.
- Multidrug-Resistant Bacteria Spreading Far Beyond Hospitals, Study Finds
A study reported in CIDRAP shows how far superbugs are spreading outside of health care, with many infections traced to community sources with no health care setting connections. Separately, ...
- Peptilogics to Participate in Musculoskeletal Infection Society (MSIS) 32nd Annual Open Scientific Meeting in Pittsburgh
Peptilogics, a biotech company engineering peptide therapeutics to improve the treatment landscape for patients with life-threatening diseases, will participate in the Musculoskeletal Infection ...
- CDC: Superbugs have spread beyond the long-term care setting
An increase in community-associated multi-drug-resistant infections is troubling, as they will be much more difficult to control and treat in a broader population, investigators say.
- Feeding Dogs Raw Meat Might Exacerbate The Antibiotic Resistance Crisis
In a new study published in the Journal of Antimicrobial Chemotherapy, a team of researchers at the University of Bristol observed that pet dogs who were predominantly on a diet of raw meat were far ...
Go deeper with Google Headlines on:
Drug resistant bacteria
Go deeper with Bing News on:
F12 lysin-based antibacterial agent
- Feed has no items.